Trial Profile
Adverse events and laboratory changes in a real-world population of patients with hepatitis C and chronic kidney disease treated with sofosbuvir-based therapy.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 18 Dec 2015
Price :
$35
*
At a glance
- Drugs Sofosbuvir (Primary) ; Ribavirin; Simeprevir
- Indications Hepatitis C
- Focus Adverse reactions
- 18 Dec 2015 New trial record